现代时代胰腺癌患者立体定向放疗与常规放疗的比较
该回顾性研究纳入104例交界可切除/潜在可切除或局部晚期胰腺癌患者,比较新辅助SBRT(中位36.0 Gy/5次)与3D/IMRT(中位50.4 Gy/28次)的临床结局。中位随访22个月,SBRT组中位OS 29.6个月 vs 3D/IMRT组24.1个月,多因素Cox回归显示放疗技术选择与OS无关(aHR=0.5,95%CI 0.2%-1.3%,P=0.18),PFS亦相似(aHR=0.9,95%CI 0.5%-1.8%,P=0.81)。作者结论认为SBRT与常规放疗技术临床结局相似,但仍需前瞻性数据进一步评估SBRT的作用。
要点
- 104例胰腺癌患者中57例(54.8%)接受SBRT,47例(45.2%)接受3D/IMRT。
- SBRT组中位OS 29.6个月 vs 3D/IMRT组24.1个月,多因素分析放疗技术与OS无关(aHR=0.5,95%CI 0.2%-1.3%,P=0.18)。
- 接受手术切除的患者OS更好(aHR=0.3,95%CI 0.1%-0.8%,P=0.01)。
核心结论
- SBRT与常规放疗技术相比临床结局相似,且治疗时间更短,可减轻患者长期治疗负担。
- 仍需前瞻性数据以更好地评估SBRT在胰腺癌患者中的作用。
研究设计与样本
- 回顾性收集德克萨斯大学MD安德森癌症中心的数据。
- 纳入接受新辅助SBRT(中位36.0 Gy/5次)、3D适形放疗(中位50.4 Gy/28次)或IMRT(中位50.4 Gy/28次)的交界可切除/潜在可切除或局部晚期胰腺癌患者。
- 共纳入104例患者,SBRT组57例(54.8%),3D/IMRT组47例(45.2%)。
- 采用Cox回归分析总生存(OS)和无进展生存(PFS)。
主要发现
- SBRT组患者年龄稍大(中位年龄70.3岁 vs 3D/IMRT组62.7岁)。
- 两组局部晚期胰腺癌比例相似(SBRT组30例,52.6%;3D/IMRT组24例,51.1%)。
- 所有患者均接受化疗。
- SBRT组接受手术切除的比例高于3D/IMRT组(38.6% vs 23.4%)。
- 中位随访22个月,共60例(57.7%)死亡:SBRT组25例(25/57,43.9%),3D/IMRT组35例(35/47,74.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性收集数据。
- 原文结论指出仍需前瞻性数据以更好地评估SBRT在胰腺癌患者中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with pancreatic cancer often receive radiation therapy before undergoing surgical resection. We compared the clinical outcomes differences between stereotactic body radiation therapy (SBRT) and 3-dimensional (3D)/intensity-modulated radiation therapy (IMRT). METHODS AND MATERIALS: We retrospectively collected data from the University of Texas MD Anderson Cancer Center. Patients with borderline resectable/potentially resectable or locally advanced pancreatic cancer receiving neoadjuvant SBRT (median, 36.0 Gy/5fx), 3D conformal radiation (median, 50.4 Gy/28 fx) or IMRT (median, 50.4 Gy/28 fx) were included. Overall survival (OS) and progression-free survival were analyzed using Cox regression. RESULTS: In total, 104 patients were included in our study. Fifty-seven patients (54.8%) were treated with SBRT, and 47 patients (45.2%) were treated with 3D/IMRT. Patients in the SBRT group were slightly older (median age: 70.3 vs 62.7 in the 3D/IMRT group). Both groups had similar proportions of patients with locally advanced pancreatic cancer (SBRT: 30, 52.6%; 3D/IMRT: 24, 51.1%). All patients were treated with chemotherapy. Patients in the SBRT group underwent more surgical resection compared with the 3D/IMRT group (38.6% vs 23.4%, respectively). At a median follow-up of 22 months, a total of 60 patients (57.7%) died: 25 (25/57, 43.9%) in the SBRT group, and 35 (35/47, 74.5%) in the 3D/IMRT group. Median OS was slightly higher in the SBRT group (29.6 months vs 24.1 months in the 3D/IMRT group). On multivariable Cox regression, the choice of radiation therapy technique was not associated with differences in OS (adjusted hazard ratios [aHR] = 0.5; 95% confidence interval [CI], 0.2%-1.3%, P = .18). Moreover, patients that underwent surgical resection had better OS (aHR = 0.3, 95% CI, 0.1%-0.8%, P = .01). Furthermore, progression-free survival was also similar between patients treated with SBRT and those treated with 3D/IMRT (aHR = 0.9, 95% CI, 0.5%-1.8%, P = .81). CONCLUSIONS: SBRT was associated with similar clinical outcomes compared with conventional radiation techniques, despite being delivered over a shorter period of time which would spare patients prolonged treatment burden. Future prospective data are still needed to better assess the role of SBRT in patients with pancreatic cancer.
引用
- Abi Jaoude J, Thunshelle CP, Kouzy R, et al. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Adv Radiat Oncol. 2021. PMID: 34934858. doi:10.1016/j.adro.2021.100763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。